Antioxidant treatment improves neonatal survival and prevents impaired cardiac function at adulthood following neonatal glucocorticoid therapy

Journal of Physiology

Volumn 591, Issue 20, 2013, Pages 5083-5093

  Niu, Youguo ^a   Herrera, Emilio A ^a   Evans, Rhys D ^b   Giussani, Dino A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; DEXAMETHASONE; NITRIC OXIDE;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; CARDIOVASCULAR FUNCTION; CHRONIC LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART AFTERLOAD; HEART DISEASE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEART PRELOAD; HEART VENTRICLE REMODELING; ISOLATED HEART; NEWBORN; NEWBORN CARE; NEWBORN MORTALITY; NONHUMAN; OXIDATIVE STRESS; PERINATAL PERIOD; PRIORITY JOURNAL; PROTECTION; RAT; SURVIVAL RATE; TREATMENT DURATION; WEANING;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; ASCORBIC ACID; CARDIAC OUTPUT; CARDIOVASCULAR DISEASES; DEXAMETHASONE; HEART RATE; MALE; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; VENTRICULAR REMODELING; VITAMIN E; VITAMINS;

EID: 84885409040     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2013.258210     Document Type: Article

References (62)

1. Adler A, Camm EJ, Hansell JA, Richter HG & Giussani DA (2010). Investigation of the use of antioxidants to diminish the adverse effects of postnatal glucocorticoid treatment on mortality and cardiac development. Neonatology 98, 73-83.
2. Baden M, Bauer C, Colle E, Klein G, Taeusch HJ & Stern L (1972). A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 50, 526-534.
3. Bal MP, de Vries WB, Steendijk P, Homoet-van der Kraak P, van der Leij FR, Baan JAN, van Oosterhout MFM & van Bel F (2009). Histopathological changes of the heart after neonatal dexamethasone treatment: Studies in 4-, 8-, and 50-week-old rats. Pediatr Res 66, 74-79.
4. Bal MP, de Vries WB, van der Leij FR, van Oosterhout MFM, Berger RMF, Baan JAN, van der Wall EE, Van Bel F & Steendijk P (2005). Neonatal glucocorticosteroid treatment causes systolic dysfunction and compensatory dilatation in early life: Studies in 4-week-old prepubertal rats. Pediatr Res 58, 46-52.
5. Bal MP, de Vries WB, van Oosterhout MFM, Baan J, van der Wall EE, van Bel F & Steendijk P (2008). Long-term cardiovascular effects of neonatal dexamethasone treatment: Hemodynamic follow-up by left ventricular pressure-volume loops in rats. J Appl Physiol 104, 446-450.
6. Balligand JL, Kelly RA, Marsden PA, Smith TW & Michel T (1993). Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 90, 347-351.
7. Benediktsson R, Lindsay RS, Noble J, Seckl JR & Edwards CRW (1993). Glucocorticoid exposure in utero: New model for adult hypertension. Lancet 341, 339-341.
8. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG & Gluud C (2008). Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 16, CD007176.
9. Camm EJ, Tijsseling D, Richter HG, Adler A, Hansell JA, Derks JB, Cross CM & Giussani DA (2011). Oxidative stress in the developing brain: Effects of postnatal glucocorticoid therapy and antioxidants in the rat. PLoS One 6, e21142.
10. Carr AC, Zhu B-Z & Frei B (2000). Potential antiatherogenic mechanisms of ascorbate (vitamin C) and α-tocopherol (vitamin E). Circ Res 87, 349-354.
11. Cummings JJ, D'Eugenio DB & Gross SJ (1989). A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 320, 1505-1510.
12. Daghini E, Chade AR, Krier JD, Versari D, Lerman A & Lerman LO (2006). Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol 290, R609-R615.
13. Dalziel SR, Walker NK, Parag V, Mantell C, Rea HH, Rodgers A & Harding JE (2005). Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet 365, 1856-1862.
14. Derks JB, Giussani DA, Jenkins SL, Wentworth RA, Visser GH, Padbury JF & Nathanielsz PW (1997). A comparative study of cardiovascular, endocrine and behavioural effects of betamethasone and dexamethasone administration to fetal sheep. J Physiol 499, 217-226.
15. de Vries W, Bal M, Homoet-van der Kraak P, Kamphuis P, van der Leij F, Baan J, Steendijk P, de Weger R, van Bel F & van Oosterhout M (2006). Suppression of physiological cardiomyocyte proliferation in the rat pup after neonatal glucocorticosteroid treatment. Basic Res Cardiol 101, 36-42.
16. de Vries WB, van Der Leij FR, Bakker JM, Kamphuis PJGH, van Oosterhout MFM, Schipper MEI, Smid GB, Bartelds B & van Bel F (2002). Alterations in adult rat heart after neonatal dexamethasone therapy. Pediatr Res 52, 900-906.
17. Docherty CC, Kalmar-Nagy J, Engelen M & Nathanielsz PW (2001). Development of fetal vascular responses to endothelin-1 and acetylcholine in the sheep. Am J Physiol Regul Integr Comp Physiol 280, R554-R562.
18. Dodic M, Abouantoun T, O'Connor A, Wintour EM & Moritz KM (2002). Programming effects of short prenatal exposure to dexamethasone in sheep. Hypertension 40, 729-734.
19. Doyle LW, Ford GW, Davis NM & Callanan C (2000). Antenatal corticosteroid therapy and blood pressure at 14 years of age in preterm children. Clin Sci 98, 137-142.
20. Fletcher AJW, McGarrigle HHG, Edwards CMB, Fowden AL & Giussani DA (2002). Effects of low dose dexamethasone treatment on basal cardiovascular and endocrine function in fetal sheep during late gestation. J Physiol 545, 649-660.
21. 15N]nitrate in biological fluids. Anal Biochem 126, 131-138.
22. Grier DG & Halliday HL (2005). Management of bronchopulmonary dysplasia in infants: Guidelines for corticosteroid use. Drugs 65, 15-29.
23. Halliday H, Ehrenkranz R & Doyle L (2009). Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 21, CD001146.
24. Halliday HL (2011). Postnatal steroids: The way forward. Arch Dis Child Fetal Neonatal Ed 96, F158-F159.
25. Halliwell B & Gutteridge JM (1984). Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219, 1-14.
26. Hauton D & Ousley V (2009). Prenatal hypoxia induces increased cardiac contractility on a background of decreased capillary density. BMC Cardiovasc Disord 9, 1.
27. Herrera EA, Verkerk MM, Derks JB & Giussani DA (2010). Antioxidant treatment alters peripheral vascular dysfunction induced by postnatal glucocorticoid therapy in rats. PLoS One 5, e9250.
28. Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H & Matsumoto T (2003). Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 92, 81-87.
29. Kelly BA, Lewandowski AJ, Worton SA, Davis EF, Lazdam M, Francis J, Neubauer S, Lucas A, Singhal A & Leeson P (2012). Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. Pediatrics 129, e1282-e1290.
30. Liggins GC (1969). Premature delivery of foetal lambs infused with glucocorticoids. J Endocrinol. 45, 515-523.
31. Liggins GC & Howie RN (1972). A controlled trial of antepartum treatment for prevention of the repiratory distress syndrome in premature infants. Pediatrics 50, 515-525.
32. Loehle M, Schwab M, Kadner S, Maner KM, Gilbert JS, Brenna JT, Ford SP, Nathanielsz PW & Nijland MJ (2010). Dose-response effects of betamethasone on maturation of the fetal sheep lung. Am J Obstet Gynecol 202, 186.e181-e187.
33. Mondo CK, Yang W-S, Zhang N & Huang T-G (2006). Anti-oxidant effects of atorvastatin in dexamethasone- induced hypertension in the rat. Clin Exp Pharmacol Physiol 33, 1029-1034.
34. Monie I (1976). Comparative development of the nervous, respiratory, and cardiovascular systems. Environ Health Perspect 18, 55-60.
35. Niu Y-G & Evans RD (2009). Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes. J Physiol 587, 3301-3315.
36. Oncu M, Gultekin F, Karaöz E, Altuntas I & Delibas N (2002). Nephrotoxicity in rats induced by chlorpryfos-ethyl and ameliorating effects of antioxidants. Hum Exp Toxicol 21, 223-230.
37. Paulus WJ, Vantrimpont PJ & Shah AM (1995). Paracrine coronary endothelial control of left ventricular function in humans. Circulation 92, 2119-2126.
38. 2+ release in cardiomyocytes. Nat Cell Biol 3, 867-873.
39. Porter WL (1993). Paradoxical behaviour of antioxidants in food and biological systems. Toxicol Ind Health 9, 93-122.
40. Poston L, Briley AL, Seed PT, Kelly FJ & Shennan AH (2006). Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): Randomised placebo-controlled trial. Lancet 367, 1145-1154.
41. Prendergast BD, Sci BM, Sagach VF & Shah AM (1997). Basal release of nitric oxide augments the Frank-Starling response in the isolated heart. Circulation 96, 1320-1329.
42. Pulgar V & Figueroa J (2006). Antenatal betamethasone administration has a dual effect on adult sheep vascular reactivity. Pediatr Res 60, 705-710.
43. Roghair RD, Wemmie JA, Volk KA, Scholz TD, Lamb FS & Segar JL (2011). Maternal antioxidant blocks programmed cardiovascular and behavioural stress responses in adult mice. Clin Sci 121, 427-436.
44. Ross J (1983). Mechanisms of cardiac contraction. Eur Heart J 4, 19-28.
45. Rueda-Clausen CF, Morton JS & Davidge ST (2011). The early origins of cardiovascular health and disease: Who, when, and how. Semin Reprod Med 29, 197-210.
46. Rybalkin SD, Yan C, Bornfeldt KE & Beavo JA (2003). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93, 280-291.
47. Serizawa T, Vogel W, Apstein C & Grossman W (1981). Comparison of acute alterations in left ventricular relaxation and diastolic chamber stiffness induced by hypoxia and ischemia. J Clin Invest 68, 91-102.
48. Shrivastava A, Lyon A & McIntosh N (2000). The effect of dexamethasone on growth, mineral balance and bone mineralisation in preterm infants with chronic lung disease. Eur J Pediatr 159, 380-384.
49. Sicard R & Werner J (1992). Dexamethasone induces a transient relative cardiomegaly in neonatal rats. Pediatr Res 31, 359-363.
50. Sissman NJ (1970). Developmental landmarks in cardiac morphogenesis: Comparative chronology. Am J Cardiol 25, 141-148.
51. Steer P (2005). The epidemiology of preterm labour. BJOG 112 (Suppl. 1), 1-3.
52. Taegtmeyer H, Hems R & Krebs H (1980). Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 186, 701-711.
53. Thibeault D, Heimes B, Rezaiekhaligh M & Mabry S (1993). Chronic modifications of lung and heart development in glucocorticoid-treated newborn rats exposed to hyperoxia or room air. Pediatr Pulm 16, 81-88.
54. Wapner R & Jobe AH (2011). Controversy: antenatal steroids. Clin Perinatol 38, 529-545.
55. Watson RE, DeSesso JM, Hurtt ME & Cappon GD (2006). Postnatal growth and morphological development of the brain: A species comparison. Birth Defects Res B Dev Reprod Toxicol 77, 471-484.
56. Weiler H, Wang Z & Atkinson S (1997). Whole body lean mass is altered by dexamethasone treatment through reductions in protein and energy utilization in piglets. Biol Neonate 71, 53-59.
57. Werner J, Sicard R, Hansen T, Solomon E, Cowett R & Oh W (1992). Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 120, 286-291.
58. Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Rikitake Y, Inoue N, Hirata K-i, Akita H & Yokoyama M (2000). Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. Hypertension 36, 97-102.
59. -1) in chronic lung disease. Arch Dis Child Fetal Neonatal Ed 96, F190-F194.
60. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh WS & Lien YJ (1998). Early dexamethasone therapy in preterm infants: A follow-up study. Pediatrics 101, e7.
61. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH & Tsai CH (2004). Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350, 1304-1313.
62. Zhang Y, Croft KD, Mori TA, Schyvens CG, McKenzie KUS & Whitworth JA (2004). The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 17, 260-265.